Zacks: Edap Tms SA (EDAP) Given $6.50 Consensus Target Price by Brokerages

Edap Tms SA (NASDAQ:EDAP) has received an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.

Brokers have set a 1 year consensus target price of $6.50 for the company, according to Zacks. Zacks has also given Edap Tms an industry rank of 100 out of 255 based on the ratings given to its competitors.

A number of equities analysts have recently issued reports on EDAP shares. Zacks Investment Research cut shares of Edap Tms from a “buy” rating to a “hold” rating in a research report on Wednesday, January 16th. ValuEngine cut shares of Edap Tms from a “hold” rating to a “sell” rating in a research report on Friday, December 21st. Finally, TheStreet raised shares of Edap Tms from a “d+” rating to a “c-” rating in a research report on Thursday, February 14th.

EDAP traded down $0.06 during trading on Friday, reaching $2.92. 2,300 shares of the stock traded hands, compared to its average volume of 40,157. The company has a current ratio of 2.41, a quick ratio of 1.97 and a debt-to-equity ratio of 0.07. The stock has a market capitalization of $86.41 million, a P/E ratio of -292.00 and a beta of 1.60. Edap Tms has a 12 month low of $1.35 and a 12 month high of $4.25.

A hedge fund recently bought a new stake in Edap Tms stock. Naples Global Advisors LLC acquired a new position in shares of Edap Tms SA (NASDAQ:EDAP) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 13,500 shares of the medical equipment provider’s stock, valued at approximately $31,000. Institutional investors and hedge funds own 10.07% of the company’s stock.

About Edap Tms

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company operates in two divisions: High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS).

Further Reading: How Do Tariffs Affect Trade Balances?

Get a free copy of the Zacks research report on Edap Tms (EDAP)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with's FREE daily email newsletter.